Mercy BioAnalytics


Mercy BioAnalytics is dedicated to saving lives through the early detection of cancer. They develop innovative, highly accurate, low-cost blood-based tests using their proprietary Mercy Halo™ platform, which leverages extracellular vesicles (EVs) for early cancer detection. Their mission is to make cancer screening broadly accessible and improve patient outcomes by detecting cancer at its earliest, most treatable stages.

Industries

biotechnology
health-care
life-science
therapeutics

Nr. of Employees

small (1-50)

Mercy BioAnalytics

Natick, Massachusetts, United States, North America


Products

Mercy Halo™ platform

A proprietary technology that uses low-cost qPCR and extracellular vesicles to identify cancer-associated biomarkers on individual EVs, enabling early detection of cancer.

Blood-based cancer screening tests

Tests developed for ovarian, lung, and other cancers that detect colocalized biomarkers on extracellular vesicles for early diagnosis.


Services

Early cancer detection tests

Development of highly sensitive, specific, and low-cost blood-based tests for early cancer detection using the Mercy Halo™ platform.

Clinical validation and studies

Conducting rigorous clinical studies and validation of their tests in populations to ensure effectiveness and reliability.

Partnership and collaboration

Working with pharmaceutical companies and other partners to accelerate clinical development, trial enrollment, and diagnostic support.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.